EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of telitacicept in adult IgA vasculitis nephropathy

Ran Zhang, Yang Yang, Fang Zeng, Dehui Liu, Wenbin Cai, Hongping Wan, Fen Cai, Sansan Tao, Gaosi Xu

Nephrology Dialysis Transplantation · 31.03.2026 · 41 (4) · 786-792

DOI: 10.1093/ndt/gfaf210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 06.10.2025. Verfasst von Ran Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Proteinuria, Vasculitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Key Project of Jiangxi Provincial Nature Science Foundation, Thousand Talents Plan, Project of Introducing and Training High-Level Talents of Innovation and Entrepreneurship in Jiangxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To investigate the efficacy and safety of telitacicept in adult immunoglobulin A vasculitis nephritis (IgAVN) patients with persistent proteinuria.

Methods

This prospective single-arm study enrolled patients aged ≥18 years diagnosed with IgAVN, an estimated glomerular filtration rate >60 mL/min/1.73 m2, previously received previous treatment with corticosteroids and immunosuppressants or had contraindications to the use of corticosteroids and immunosuppressants, and a 24-h urinary protein–creatinine ratio (UPCR) >1 g/g. Patients received telitacicept 160 mg weekly for 6 months.

Results

A total of 13 patients were enrolled in this study, of which 7 were males. The mean age of patients was 35 years. The mean time since diagnosis before telitacicept treatment was 12.6 months. After 6 months of treatment with telitacicept, the mean 24-h UPCR decreased from a baseline value of 2.9 ± 0.8 to 0.5 ± 0.3 g/g (P < .001). At 9 months, 12 patients (92.3%) achieved complete remission, and the mean 24-h UPCR decreased to 0.4 ± 0.1 g/g. Additionally, the renal function of patients remained stable, urinary red blood cells, blood CD4+ T cells, CD19+ B cells, immunoglobulin levels were decreased compared with the baseline values in all patients at 9 months (P < .05). No severe adverse events were observed.

Conclusion

Additional telitacicept significantly increased the complete remission rate of IgAVN with persistent proteinuria and stabilized renal function, without serious adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAProteinuriaVasculitisHumansMaleAdultFemaleProspective StudiesMiddle AgedGlomerular Filtration RatePrognosisFollow-Up StudiesYoung AdultImmunosuppressive AgentsImmunoglobulin ARecombinant Fusion Proteins

Stichwörter der Autor:innen

hematuresisimmunoglobulin A vasculitis nephritisproteinuriatelitacicept

Substanzen

Immunosuppressive AgentsImmunoglobulin AtelitaciceptRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Nephrology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
  • Jiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, P. R. China.
  • Department of Nephrology, Ganzhou People's Hospital, Ganzhou, P. R. China.
  • Department of Pediatrics, Gaoxin Branch of the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
  • Department of Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.
  • Department of Rheumatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, P. R. China.

Förderung

  • Key Project of Jiangxi Provincial Nature Science Foundation
  • Thousand Talents Plan
  • Project of Introducing and Training High-Level Talents of Innovation and Entrepreneurship in Jiangxi Province
  • Jiangxi Province Key Laboratory of Molecular Medicine

Zitieren

APA

Zhang, R., Yang, Y., Zeng, F., Liu, D., Cai, W., Wan, H., Cai, F., Tao, S., & Xu, G. (2026). Efficacy and safety of telitacicept in adult IgA vasculitis nephropathy. Nephrology Dialysis Transplantation, 41(4), 786-792. https://doi.org/10.1093/ndt/gfaf210

Vancouver

Zhang R, Yang Y, Zeng F, Liu D, Cai W, Wan H, et al. Efficacy and safety of telitacicept in adult IgA vasculitis nephropathy. Nephrology Dialysis Transplantation. 2026;41(4):786-792. doi:10.1093/ndt/gfaf210

BibTeX
@article{Zhang2026,
  author = {Zhang, Ran and Yang, Yang and Zeng, Fang and Liu, Dehui and Cai, Wenbin and Wan, Hongping and Cai, Fen and Tao, Sansan and Xu, Gaosi},
  title = {Efficacy and safety of telitacicept in adult IgA vasculitis nephropathy},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  volume = {41},
  number = {4},
  pages = {786--792},
  doi = {10.1093/ndt/gfaf210}
}
Kostenlos starten →